CC-486 DLBCL-001 study design. (A) Overall study design. (B) Dosing schedule. DLBCL, diffuse large B-cell lymphoma; ECOG PS, Eastern Cooperative Oncology Group performance status; FL, follicular lymphoma; IPI, International Prognostic Index; R-CHOP, rituximab plus cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisolone; RP2D, recommended phase 2 dose.